These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 25009215

  • 1. Concomitant low-dose doxorubicin treatment and exercise.
    Sturgeon K, Schadler K, Muthukumaran G, Ding D, Bajulaiye A, Thomas NJ, Ferrari V, Ryeom S, Libonati JR.
    Am J Physiol Regul Integr Comp Physiol; 2014 Sep 15; 307(6):R685-92. PubMed ID: 25009215
    [Abstract] [Full Text] [Related]

  • 2. Over-expression of calpastatin aggravates cardiotoxicity induced by doxorubicin.
    Wang Y, Zheng D, Wei M, Ma J, Yu Y, Chen R, Lacefield JC, Xu H, Peng T.
    Cardiovasc Res; 2013 Jun 01; 98(3):381-90. PubMed ID: 23455548
    [Abstract] [Full Text] [Related]

  • 3. Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway.
    Zhu W, Soonpaa MH, Chen H, Shen W, Payne RM, Liechty EA, Caldwell RL, Shou W, Field LJ.
    Circulation; 2009 Jan 06; 119(1):99-106. PubMed ID: 19103993
    [Abstract] [Full Text] [Related]

  • 4. Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro.
    Mukhopadhyay P, Rajesh M, Bátkai S, Kashiwaya Y, Haskó G, Liaudet L, Szabó C, Pacher P.
    Am J Physiol Heart Circ Physiol; 2009 May 06; 296(5):H1466-83. PubMed ID: 19286953
    [Abstract] [Full Text] [Related]

  • 5. Exercise Protects Skeletal Muscle during Chronic Doxorubicin Administration.
    Dickinson JM, D'Lugos AC, Mahmood TN, Ormsby JC, Salvo L, Dedmon WL, Patel SH, Katsma MS, Mookadam F, Gonzales RJ, Hale TM, Carroll CC, Angadi SS.
    Med Sci Sports Exerc; 2017 Dec 06; 49(12):2394-2403. PubMed ID: 28767526
    [Abstract] [Full Text] [Related]

  • 6. Spironolactone Attenuates Doxorubicin-induced Cardiotoxicity in Rats.
    Liu G, Liu Y, Wang R, Hou T, Chen C, Zheng S, Dong Z.
    Cardiovasc Ther; 2016 Aug 06; 34(4):216-24. PubMed ID: 27097055
    [Abstract] [Full Text] [Related]

  • 7. Doxorubicin triggers bioenergetic failure and p53 activation in mouse stem cell-derived cardiomyocytes.
    Cunha-Oliveira T, Ferreira LL, Coelho AR, Deus CM, Oliveira PJ.
    Toxicol Appl Pharmacol; 2018 Jun 01; 348():1-13. PubMed ID: 29653124
    [Abstract] [Full Text] [Related]

  • 8. Both aerobic exercise and resveratrol supplementation attenuate doxorubicin-induced cardiac injury in mice.
    Dolinsky VW, Rogan KJ, Sung MM, Zordoky BN, Haykowsky MJ, Young ME, Jones LW, Dyck JR.
    Am J Physiol Endocrinol Metab; 2013 Jul 15; 305(2):E243-53. PubMed ID: 23695218
    [Abstract] [Full Text] [Related]

  • 9. Exercise preconditioning provides long-term protection against early chronic doxorubicin cardiotoxicity.
    Hydock DS, Lien CY, Jensen BT, Schneider CM, Hayward R.
    Integr Cancer Ther; 2011 Mar 15; 10(1):47-57. PubMed ID: 21382960
    [Abstract] [Full Text] [Related]

  • 10. Neuregulin-1 attenuated doxorubicin-induced decrease in cardiac troponins.
    Bian Y, Sun M, Silver M, Ho KK, Marchionni MA, Caggiano AO, Stone JR, Amende I, Hampton TG, Morgan JP, Yan X.
    Am J Physiol Heart Circ Physiol; 2009 Dec 15; 297(6):H1974-83. PubMed ID: 19801490
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of AMPK signalling by doxorubicin: at the crossroads of the cardiac responses to energetic, oxidative, and genotoxic stress.
    Gratia S, Kay L, Potenza L, Seffouh A, Novel-Chaté V, Schnebelen C, Sestili P, Schlattner U, Tokarska-Schlattner M.
    Cardiovasc Res; 2012 Aug 01; 95(3):290-9. PubMed ID: 22461523
    [Abstract] [Full Text] [Related]

  • 12. Resolvin E1 protects against doxorubicin-induced cardiotoxicity by inhibiting oxidative stress, autophagy and apoptosis by targeting AKT/mTOR signaling.
    Zhang J, Wang M, Ding W, Zhao M, Ye J, Xu Y, Wang Z, Ye D, Li D, Liu J, Wan J.
    Biochem Pharmacol; 2020 Oct 01; 180():114188. PubMed ID: 32750329
    [Abstract] [Full Text] [Related]

  • 13. Oxidative stress on cardiotoxicity after treatment with single and multiple doses of doxorubicin.
    Segredo MP, Salvadori DM, Rocha NS, Moretto FC, Correa CR, Camargo EA, de Almeida DC, Reis RA, Freire CM, Braz MG, Tang G, Matsubara LS, Matsubara BB, Yeum KJ, Ferreira AL.
    Hum Exp Toxicol; 2014 Jul 01; 33(7):748-60. PubMed ID: 24275640
    [Abstract] [Full Text] [Related]

  • 14. Acute exercise protects against doxorubicin cardiotoxicity.
    Wonders KY, Hydock DS, Schneider CM, Hayward R.
    Integr Cancer Ther; 2008 Sep 01; 7(3):147-54. PubMed ID: 18815146
    [Abstract] [Full Text] [Related]

  • 15. Marein Alleviates Doxorubicin-Induced Cardiotoxicity through FAK/AKT Pathway Modulation while Potentiating its Anticancer Activity.
    Xu J, Lv M, Ni X.
    Cardiovasc Toxicol; 2024 Aug 01; 24(8):818-835. PubMed ID: 38896162
    [Abstract] [Full Text] [Related]

  • 16. Insulin-like growth factor II receptor-α is a novel stress-inducible contributor to cardiac damage underpinning doxorubicin-induced oxidative stress and perturbed mitochondrial autophagy.
    Pandey S, Kuo WW, Shen CY, Yeh YL, Ho TJ, Chen RJ, Chang RL, Pai PY, Viswanadha VP, Huang CY, Huang CY.
    Am J Physiol Cell Physiol; 2019 Aug 01; 317(2):C235-C243. PubMed ID: 31116582
    [Abstract] [Full Text] [Related]

  • 17. Diverging effects of enalapril or eplerenone in primary prevention against doxorubicin-induced cardiotoxicity.
    Hullin R, Métrich M, Sarre A, Basquin D, Maillard M, Regamey J, Martin D.
    Cardiovasc Res; 2018 Feb 01; 114(2):272-281. PubMed ID: 29016737
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of cyclin-dependent kinase 7 mitigates doxorubicin cardiotoxicity and enhances anticancer efficacy.
    Chen J, Wei J, Xia P, Liu Y, Belew MD, Toohill R, Wu BJ, Cheng Z.
    Cardiovasc Res; 2024 Jul 31; 120(9):1024-1036. PubMed ID: 38646672
    [Abstract] [Full Text] [Related]

  • 19. Liposomal doxorubicin attenuates cardiotoxicity via induction of interferon-related DNA damage resistance.
    Gyöngyösi M, Lukovic D, Zlabinger K, Spannbauer A, Gugerell A, Pavo N, Traxler D, Pils D, Maurer G, Jakab A, Riesenhuber M, Pircher A, Winkler J, Bergler-Klein J.
    Cardiovasc Res; 2020 Apr 01; 116(5):970-982. PubMed ID: 31346605
    [Abstract] [Full Text] [Related]

  • 20. Doxorubicin triggers splenic contraction and irreversible dysregulation of COX and LOX that alters the inflammation-resolution program in the myocardium.
    Jadapalli JK, Wright GW, Kain V, Sherwani MA, Sonkar R, Yusuf N, Halade GV.
    Am J Physiol Heart Circ Physiol; 2018 Nov 01; 315(5):H1091-H1100. PubMed ID: 30074834
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.